Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis

Cardiovascular Therapeutics

Volumn 28, Issue 5, 2010, Pages

  Turiel, M ^a   Tomasoni, L ^a   Sitia, S ^a   Cicala, S ^a   Gianturco, L ^a   Ricci, C ^a,d   Atzeni, F ^b   De Gennaro Colonna, V ^a   Longhi, M ^c   Sarzi Puttini, P ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Interventional cardiology; Ischemic heart disease; Lipids disorder atherosclerosis; Vascular biology

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; METHOTREXATE; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY FLOW RESERVE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARGININE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CAROTID ARTERY, COMMON; CASE-CONTROL STUDIES; CORONARY CIRCULATION; CORONARY VESSELS; ECHOCARDIOGRAPHY, DOPPLER; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ITALY; MALE; METHOTREXATE; MICROCIRCULATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955267720     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00119.x     Document Type: Article

References (59)

1. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007 21 : 871 883.
2. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001 44 : 2737 2745.
3. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003 107 : 1303 1307.
4. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis Rheum 2005 52 : 722 732.
5. Folson AR, Aleksinc N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (AIRC) study. Am Heart J 2002 144 : 233 238.
6. Pradhan AD, Manson JE, Rossoux JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease - prospective analysis from the Women's Health Initiative observational study. JAMA 2002 288 : 980 987.
7. Gerli R, Schillaci G, Giordano A, et al. CD4+ CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004 109 : 2744 2748.
8. Akhavani MA, Larsen H, Paleolog E. Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. Scand J Rheumatol 2007 36 : 83 90.
9. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005 32 : 435 442.
10. McEntegart A, Capell HA, Madhok R. Predicting coronary risk in rheumatoid arthritis. Arthritis Rheum 2001 44 : S53.
11. Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimm Rev 2009 8 : 663 667.
12. Salliot C, Van Der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis 2009 68 : 1100 1104.
13. Wislowska M, Sypula S, Kowalick I. Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 1998 17 : 369 377.
14. Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006 18 : 289 297.
15. Gonzales-Gay MA, Gonzalez-Juanatey C, Miranda-Filloy JA, Garcia-Porrua C, Llorca J, Martin J. Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother 2006 60 : 673 677.
16. Quinn MA, Cox S. The evidence for early intervention. Rheum Dis Clin North Am 2005 31 : 575 589.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 31 : 315 324.
18. Turiel M, Peretti R, Sarzi-Puttini P, Atzeni F, Doria A. Cardiac imaging techniques in systemic autoimmune diseases. Lupus 2005 14 : 727 731.
19. Rigo F, Gherardi S, Galderisi M, et al. The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy. Eur Heart J 2006 27 : 1319 1323.
20. Sidhu PS, Allen PL. Ultrasound assessment of internal carotid artery stenosis. Clin Radiol 1997 52 : 654 658.
21. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001 358 : 2096 2097.
22. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 1999 99 : 1141 1146. (Pubitemid 29120084)
23. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998 98 : 1842 1847.
24. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001 38 : 111 116.
25. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997 95 : 2068 2074.
26. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharm 1999 33 : 652 658.
27. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002 287 : 1420 1426.
28. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001 358 : 2127 2128.
29. Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005 95 : 729 733.
30. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmen KH, Ritz E. Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996 11 : 2449 2452.
31. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 2005 10 : S3 S9.
32. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: A novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008 17 : 609 615.
33. Hansel S, Lassing G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003 170 : 177 180.
34. Nurten T, Nihal S, Gonca O, Ozgur A, Halil Y, Filiz B, Barbaros B. Role of neutrophils in arginine-asymmetric dimethylarginine pathway subsequent to endotoxemia. Ann N Y Acad Sci 2009 1173 : 55 59.
35. Turiel M, Atzeni F, Tomasoni L, et al. Non-invasive assessment of coronary flow reserve and ADMA levels: A case-control study of early rheumatoid arthritis patients. Rheumatology 2009 48 : 834 839.
36. Van Der Kooji SM, Allaart CF, Dijkmans BA, Breeveld FC. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008 20 : 287 294.
37. Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction. Diabetes Care 2000 23 : 1108 1112.
38. Van Der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993 20 : 579 581.
39. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003 289 : 2560 2571.
40. Sahn DJ, De Maria A, Kisslo J, Weyman A. The Committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978 58 : 1072 1113.
41. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989 2 : 358 367.
42. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977 55 : 613 618.
43. Qiunones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Doppler quantification task force of the nomenclature and standards committee of the American Society of Echocardiography. Recommendations for quantification of Doppler Echocardiography. J Am Soc Echocardiogr 2002 15 : 167 184.
44. Zwiebel WJ, Knighton R. Protocol for color-duplex examination of the carotid arteries and Doppler evaluation of carotid stenoses. In : Zwiebel WJ, editor. Introduction to Vascular Ultrasonography, 3rd ed. Philadelphia : WB Saunders, 1992 95 104, 123 132.
45. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem 1972 18 : 499 502.
46. Teerlink T. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol Med 2005 108 : 263 274.
47. Bland JM, Altman DJ. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 1 : 307 310.
48. R Development Core Team. R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria. 2005 ISBN 3-900051-07-0.
49. Del Rincon I, O'Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 2007 195 : 354 360.
50. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high grade " systemic inflammation accelerates cardiovascular risk in rheumatoid arthritis. Circulation 2003 108 : 2957 2963.
51. Del Rincon I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004 50 : 3813 3822.
52. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002 359 : 1173 1177.
53. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-(treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002 106 : 2184 2187.
54. Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ. Anti-tumor necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006 26 : 1125 1131.
55. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: Effects of anti-TNF drugs. Exp Opin Pharmacother 2008 9 : 1121 1128.
56. Rueda-Clausen CF, Lòpez-Jaramillo P, Luengas C, del Pilar Oubina M, Cachofeiro V, Lahera V. Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects. Mediators Inflamm Epub 2009.
57. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and noninvasive vascular markers: The multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008 199 : 3 11.
58. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliot HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000 98 : 531 535.
59. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004 109 : 1955 1959.